0000950170-25-105233
SEC filingNo MD&A data found in the provided document content.
No MD&A narrative provided for analysis.
As of June 30, 2025, Diodes held $317.0 million in cash and cash equivalents, plus $10.3 million in short-term investments, for total liquid assets of $327.3 million. Total debt stood at $53.4 million, comprising $27.6 million in short-term lines of credit and $25.8 million in long-term debt (net of current portion). Shareholders' equity was $1.877 billion. Inventory increased to $482.7 million from $474.9 million at year-end 2024, driven by higher raw materials and work-in-progress.
The Notes disclose $40.1 million in non-cancelable purchase commitments for capital expenditures (primarily manufacturing equipment) and $69.6 million in wafer purchase commitments scheduled through 2031. Additionally, the Company has a defined benefit plan underfunded liability of $5.2 million, with required annual contributions of GBP 2.0 million through 2028 and a final payment of GBP 1.5 million in 2029. A related-party wafer purchase agreement with Nuvoton for $5.7 million runs through Q2 2026.
During the six months ended June 30, 2025, Diodes repurchased 211,000 shares for $10.0 million. No dividends were paid. Capital expenditures totaled $36.3 million (5.2% of net sales). The Company had net debt repayments of $5.0 million, with $6.5 million in new long-term debt and $3.7 million in repayments. No new buyback authorization was disclosed.
The Company operates as a single segment (standard semiconductor products). Geographic disaggregation shows Asia contributed $412.0 million (59.0%) of net sales for the six months ended June 30, 2025, Americas $235.3 million (33.7%), and Europe $51.0 million (7.3%). By shipment destination, Asia accounted for $544.3 million, Europe $90.1 million, and Americas $63.9 million. Distribution sales were $446.5 million (63.9%) vs. direct sales of $251.8 million (36.1%). Two customers each exceeded 10% of net sales in the quarter.
Operating cash flow (CFO) of $98.3M for the six months ended June 30, 2025, was a significant improvement from a use of $16.7M in the prior-year period. Net income of $41.3M was augmented by non-cash charges (depreciation $60.1M, amortization $11.7M, share-based compensation $12.2M) and a $25.6M investment gain. The primary driver of the CFO swing was a large working capital release: accounts receivable declined $21.3M (vs. a $12.9M increase in 2024) and inventory increased only $6.0M (vs. a $74.4M increase in 2024). Accounts payable rose $9.5M, while accrued liabilities fell $17.4M.
Capital expenditures of $36.3M were nearly unchanged from $38.3M in the prior year, representing a capex intensity of 88% of CFO. Free cash flow (CFO minus capex) was $61.9M, a sharp reversal from a negative $55.1M in H1 2024. The company used $10.0M for share repurchases and $13.5M for net changes in noncontrolling interest, with no dividends paid. Investing activities also included $49.2M in purchases of equity securities and $15.9M in proceeds from sale of a subsidiary. Overall, cash generation improved markedly, driven by working capital normalization and disciplined capex.